T Igawa Selected Research

Neutralizing Antibodies

2/2014

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

T Igawa Research Topics

Disease

3	Rheumatoid Arthritis 01/2022 - 01/2020
2	Hemorrhage 02/2014 - 02/2014
1	Dermatomyositis (Dermatopolymyositis) 01/2021
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021
1	Rheumatic Diseases (Rheumatism) 01/2021
1	Necrosis 01/2020
1	Lupus Nephritis 04/2019
1	Hemophilia A (Haemophilia) 02/2014
1	Autoimmune Diseases (Autoimmune Disease) 10/2008
1	Neoplasm Metastasis (Metastasis) 03/2001
1	Prostatic Neoplasms (Prostate Cancer) 07/2000

Drug/Important Bio-Agent (IBA)

2	Antirheumatic Agents (DMARD)IBA 01/2022 - 01/2020
2	Abatacept (Orencia)FDA Link 01/2021 - 01/2020
2	Hemostatics (Antihemorrhagics)IBA 02/2014 - 02/2014
1	Janus Kinase InhibitorsIBA 01/2022
1	Janus KinasesIBA 01/2022
1	AntibodiesIBA 01/2021
1	AntigensIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Interleukin-15 (Interleukin 15)IBA 01/2021
1	Anti-Citrullinated Protein AntibodiesIBA 01/2020
1	Tumor Necrosis Factor InhibitorsIBA 01/2020
1	emicizumabIBA 02/2014
1	Factor IXa (Coagulation Factor IXa)IBA 02/2014
1	Neutralizing AntibodiesIBA 02/2014
1	Interleukin-27 (Interleukin 27)IBA 10/2008

Therapy/Procedure

2	Aftercare (After-Treatment) 01/2021 - 03/2001
2	Therapeutics 04/2019 - 07/2000